Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1981 to 1995 of 9005 results

  1. Bronchoscopic intrabullous autologous blood instillation (BIABI) for the therapy of Emphysema: intractable with pneumothorax, COPD & Lung cancer, patients requiring lung biopsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Kinetic Oscillation Stimulation to the nasal cavity for the preventive treatment of adults diagnosed with chronic migraine

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Inserting a bupivicaine-collagen implant into a surgical wound for postoperative analgesia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Extracorporeal bioartificial liver assist therapy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Hysteroscopic proximal tubal cannulation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Extradural motor cortex stimulation (EMCS) for Parkinson's disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Migraine trigger site deactivation surgery

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  8. Transcranial direct current stimulation (tDCS) for the treatment of refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 28 April 2026.

    Technology appraisal guidance
    In consultation

  10. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

    In development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11987 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Rezafungin for untreated invasive candidiasis [TSID10768]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Pelvic floor dysfunction

    Awaiting development Reference number: GID-QS10129 Expected publication date: TBC

    Quality standard
    Awaiting development

  15. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development Reference number: GID-TA11405 Expected publication date: TBC

    Technology appraisal guidance
    In development